#national institute for research in tuberculosis recruitment

[sudheervanguri]

The Calcutta School of Tropical Medicine is currently seeking a qualified and experienced Clinical Research Coordinator for an exciting research project. This position, based in Kolkata, is ideal for candidates with an MBBS, BDS, or M. Pharm degree and experience in infectious diseases or health-related projects. The role offers a competitive salary and the opportunity to contribute to a significant research initiative led by the National Institute of TB Research and Development (NITRD). Job Location and Type Location: Calcutta School of Tropical Medicine, 108 Chittaranjan Avenue, Kolkata - 700073 Job Type: Full-Time, Temporary (One Year) Salary: Rs. 50,000/- per month Key Responsibilities As a Clinical Research Coordinator, you will play a critical role in a multicenter research project evaluating the diagnostic accuracy of a point-of-care urine lipoarabinomannon screening assay for HIV-associated tuberculosis in India. Your responsibilities will include: Project Coordination: Oversee the day-to-day operations of the research project, ensuring that all activities are conducted according to the project plan. Data Management: Collect, manage, and analyze clinical data, maintaining accuracy and confidentiality. Participant Recruitment: Coordinate the recruitment of study participants, ensuring adherence to ethical guidelines and protocols. Compliance: Ensure that the project complies with all relevant regulatory requirements and ethical standards. Reporting: Prepare detailed reports on the progress of the project and communicate findings to the research team. Qualifications and Requirements To be considered for the role of Clinical Research Coordinator at the Calcutta School of Tropical Medicine, candidates must meet the following qualifications: Essential Qualification: MBBS, BDS, or M. Pharm from a recognized university. Desirable Qualification: An additional postgraduate degree or diploma in infectious diseases or a related field. Experience in clinical research, particularly in infectious disease or health-related projects. [caption id="attachment_100400" align="aligncenter" width="930"] Clinical Research Coordinator Vacancy at Calcutta School of Tropical Medicine[/caption] Other Requirements: At least five years of work experience in a medical or related field, with a focus on research. Strong communication skills and a basic knowledge of computer applications. Age limit: Up to 50 years. Application Process Interested candidates are required to attend a walk-in interview at the Calcutta School of Tropical Medicine on 04.09.2024 at 11:00 AM. Registration for the interview will take place between 10:00 AM and 11:00 AM on the same day. Candidates must bring the following documents for verification: Original certificates/testimonials One self-attested copy of educational testimonials (including age proof, mark sheets, certificates, and work experience) Bio-Data A formal application addressed to the Director, School of Tropical Medicine, Kolkata Please Note: The appointment is purely on a temporary basis and can be terminated with one month's notice from either side. No TA/DA will be provided for attending the interview. About the Calcutta School of Tropical Medicine The Calcutta School of Tropical Medicine is one of the oldest and most prestigious research institutes in India, focusing on tropical diseases and public health. This vacancy offers a unique opportunity to work with a leading research team on a project that has the potential to make a significant impact on public health. For full details and official notifications, visit here.

[ambitiousbaba]

ICMR NIRT Recruitment 2024

ICMR NIRT Recruitment 2024 : 15 Post for Project Driver cum Mechanic ICMR National Institute for Research in Tuberculosis (ICMR NIRT) has released the notification for the recruitment of for the Post of Project Driver cum Mechanic with 15 Vacancies. Candidates can check the eligibility criteria from the official notification and apply Online Between 06 May 2024 to 09 May 2024. Here we are…

[latestgovtjobnews]

New Delhi's National Institute of Tuberculosis seeks Indian Director with medical background by February 6, 2024.

New Post has been published on https://www.jobsarkari.in/new-delhis-national-institute-of-tuberculosis-seeks-indian-director-with-medical-background-by-february-6-2024/

New Delhi's National Institute of Tuberculosis seeks Indian Director with medical background by February 6, 2024.

The National Institute of Tuberculosis and Respiratory Diseases is seeking applications for the position of Director. The institute, located in New Delhi, is an autonomous body under the Ministry of Health and Family Welfare, Government of India. The Director will be appointed through direct recruitment or deputation of suitable officers.

Applicants must have a medical qualification recognized under the Indian Medical Council Act of 1956 and the National Medical Commission Act of 2019. They should also hold a recognized postgraduate qualification in Tuberculosis and Respiratory Diseases, Tuberculosis and Chest Diseases, or an allied specialty. Additionally, candidates must have at least 18-16 years of clinical experience after obtaining their PG Diploma/Degree.

Candidates should have a minimum of 5 years of experience in running a teaching, training, or research institution as the Head or Head of Department. Alternatively, they should have 10 years of experience as a Professor or equivalent. Registration with the Central/State Medical Council is also required.

Candidates currently employed in Central Government/State Government Departments/Public Sector undertakings/Semi-Government/Statutory or Autonomous Organizations should apply through the proper channel. Proof of the details provided in the application may be requested at a later stage.

Only Indian Nationals are eligible to apply for this position. The prescribed essential qualifications are minimum requirements, and possessing them does not guarantee an interview invitation.

Applications must be submitted in the prescribed format, which can be downloaded from the institute’s websites. The completed application should be sent to the Director of the National Institute of Tuberculosis and Respiratory Diseases by 3:30 pm on February 6, 2024. In addition, candidates are required to send their bio-data via email to avoid postal delays.

Incomplete applications or those received after the closing date will not be considered. The envelope containing the application should be marked ‘Application for the Post of Director, NITRD.’

This is a summary of the job advertisement for the Director position at the National Institute of Tuberculosis and Respiratory Diseases in New Delhi.

Applications are invited for the post of Director at the National Institute of Tuberculosis & Respiratory Diseases in New Delhi.

The post can be filled through direct recruitment or deputation of suitable officers.

Eligibility criteria include a medical qualification, a recognized PG qualification in Tuberculosis and Respiratory Diseases, and minimum clinical experience.

Candidates should have at least 5 years of experience in running a teaching/training/research institution or 10 years of experience as a Professor or equivalent.

Candidates must be registered with the Central/State Medical Council.

Candidates working in government departments or organizations should apply through proper channel.

The prescribed application form can be downloaded from the institute’s website and should be submitted by the specified deadline.

Incomplete applications or those received after the closing date will not be considered.

Job Opportunity at National Institute of Tuberculosis

Applications are invited for the post of Director at the National Institute of Tuberculosis & Respiratory Diseases in New Delhi.

The institute is an autonomous body under the Ministry of Health and Family Welfare, Govt. of India.

The position offers a competitive salary and benefits package.

Recruitment Options

The post can be filled through direct recruitment or deputation of suitable officers.

Direct recruitment is preferred, but deputation is also accepted for officers fulfilling the qualification criteria.

Candidates should carefully review the eligibility criteria before applying.

Eligibility Criteria

A medical qualification included in the first or second schedule or Part II of the third schedule to Indian Medical Council Act of 1956.

A recognized PG qualification in Tuberculosis and Respiratory Diseases or allied specialties.

Clinical experience of not less than 18/16 years after PG Diploma/Degree.

At least 5 years experience of running an important teaching/training/research institution or 10 years experience as a Professor or equivalent.

Additional Requirement

Candidates must be registered with the Central/State Medical Council.

General Conditions: Candidates working in government departments or organizations should apply through proper channel.

The prescribed application form can be downloaded from the institute’s website.

Application Submission

Completed applications should be submitted to the Director, National Institute of Tuberculosis & Respiratory Diseases, New Delhi.

The deadline for submission is 3.30 pm on February 6, 2024.

Candidates are also required to send their bio-data in the prescribed format through email to s.gupta@nitrd.nic.in.

Importance of Fulfilling Eligibility Criteria

Meeting the essential qualifications is a bare minimum requirement.

Mere possession of the qualifications does not guarantee an interview invitation.

Candidates should ensure they fulfill all the eligibility criteria before applying.

Benefits of Working at National Institute of Tuberculosis

A challenging and rewarding opportunity to contribute to the field of Tuberculosis and Respiratory Diseases.

Access to state-of-the-art facilities and resources for research and training.

Collaboration opportunities with renowned experts in the field.

Reminder of Application Deadline

The deadline for submission is 3.30 pm on February 6, 2024.

Late or incomplete applications will not be considered.

Applicants should submit their applications as per the specified format and through the proper channels.

Opportunity to Lead at National Institute of Tuberculosis

The position of Director at the National Institute of Tuberculosis offers a unique opportunity to make a significant impact in the field of Tuberculosis and Respiratory Diseases.

If you meet the eligibility criteria, submit your application before the deadline to be considered for this prestigious position.

Don’t miss out on this chance to shape the future of respiratory healthcare in India.

[edu276]

AJIMS, Mangalore- Courses, Fees, Admission 2023, Placements

AJ Institute of Medical Sciences (AJIMS) is a renowned private medical institute located in Mangalore, Karnataka. Established in the year 2002, the institute is affiliated with the Rajiv Gandhi University of Health Sciences (RGUHS) and is approved by the Medical Council of India (MCI). AJIMS is known for its high-quality medical education and has also received accreditation from the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

AJIMS offers a range of programs at the undergraduate, postgraduate, and diploma levels. The flagship undergraduate program is the Bachelor of Medicine, Bachelor of Surgery (MBBS). At the postgraduate level, the institute offers programs such as Doctor of Medicine (MD), Master of Surgery (MS), Master of Chirurgiae (M. Ch.), and Doctorate of Medicine (DM). Additionally, AJIMS provides diploma programs including Diploma in Tuberculosis and Chest Diseases (DTCD) and Diploma in Child Health (DCH).

To secure admission to any of the programs offered by AJIMS, candidates must ensure they meet the minimum educational qualification requirements specified by the college. The admission process typically involves qualifying entrance examinations such as NEET (National Eligibility cum Entrance Test) for MBBS and postgraduate medical courses. Candidates must also satisfy other criteria such as academic performance and fulfilling the eligibility norms set by the college and regulatory authorities.

AJ Institute of Medical Sciences has a strong focus on providing excellent placement opportunities to its students. The college has ties with leading hospitals, healthcare institutions, and medical organizations, which facilitates the placement process. Students are exposed to practical training, clinical rotations, and internships to enhance their skills and prepare them for a successful medical career. The specific details of placement statistics and top recruiters can be obtained from the college's placement cell.

AJIMS is committed to providing a conducive learning environment for students, equipped with state-of-the-art infrastructure and modern facilities. The institute emphasizes practical training, research, and community engagement to nurture competent healthcare professionals.

[latestbreakingnewsupdates]

National Institute for Research in Tuberculosis Recruitment 2020: Junior Consultant & Scientist C

National Institute for Research in Tuberculosis Recruitment 2020: Junior Consultant & Scientist C

ICMR – National Institute for Research in Tuberculosis Recruitment 2020: Junior Consultant & Scientist C

Applications are invited for filling up the following vacancies.

1. Scientist C (Non-Medical): 02 Posts Qualification: A first class Master Degree in Economics/ Health Economics/ Econometrics/ Statistics/ Actuarial science/ Data analytics/ Public Health. Experience: 04 years Age Limit:

[blackkudos]

Frederick Douglass Patterson

Frederick Douglass Patterson (October 10, 1901 – April 26, 1988) was an American former president of what is now Tuskegee University (1935–1953) and founder of the United Negro College Fund (1944, UNCF). In 1987, President Ronald Reagan awarded Dr. Patterson the Presidential Medal of Freedom, the nation's highest civilian honor. In 1988, he was awarded the Spingarn Medal from the NAACP.

Early life and family

Frederick Douglass Patterson was born on October 10, 1901 in Washington, D.C. to Mamie Lucille and William Ross Patterson. He was named after the great abolitionist and D.C. resident Frederick Douglass. Patterson was orphaned by the age of 2 when both of his parents died from tuberculosis. He then moved in with his sister Bessie, his primary caregiver, who sacrificed to ensure him a good education. She dedicated nearly half her $20 monthly salary to enroll him in the private elementary school of Samuel Huston College (currently Huston-Tillotson College) where his affinity for education quickly shined through. Thelma Dale Perkins, born in 1915, was a niece of his.

Education and his path to academic excellence

By the age of 31, Patterson had attained three educational degrees: a Doctorate degree of Veterinary Medicine and Master of Science degree from Iowa State University (ISU), and a Doctorate of Philosophy from Cornell University.

He studied in the Agriculture Department at the Prairie View Normal and Industrial Institute (now Prairie View A&M University) in Texas. Later, he enrolled at Iowa State College (now Iowa State University or ISU) in the College of Veterinary Medicine, where he graduated with a Doctor of Veterinary Medicine in 1923 and a Master of Science in 1927.

His journey to academic accomplishment was not without its roadblocks. He was the only African American working at the Iowa State College veterinary clinic, where he learned important personal lessons about race and society. In his autobiography, reflecting on the experiences, he writes, "I learned a lesson with regard to race that I never forgot: how people feel about you reflects the way you permit yourself to be treated. If you permit yourself to be treated differently, you are condemned to an unequal relationship." The same year Patterson received his Doctorate from Iowa State College in 1923, the College's first African American student athlete, Jack Trice, died from injuries sustained in a football game.

He earned a Doctorate of Philosophy in 1932 in Veterinary Pathology from Cornell University.

Professional career

Patterson taught veterinary medicine for four years at Virginia State College while serving as the Director of Agriculture. From there, he became head of the veterinary division, then the director of the School of Agriculture at the Tuskegee Institute.

In 1935, at the young age of 33, he had distinguished himself enough to be named the third President of Tuskegee Institute.

At Tuskegee Institute (between 1935-1953), President Patterson was responsible for transforming the Institute into a full-fledged university with graduate programs that exist to this day. Over the course of his Presidency he founded the School of Veterinary Medicine, the Commercial Dietetics program, and spearheaded the University's engineering and commercial aviation programs. All of these programs uniquely situated African Americans and Tuskegee University in a position where they could provide highly skilled interns for prestigious internships in emerging fields.

Legacy

In 1944 founded two institutions which would largely shape his overall legacy: the School of Veterinary Medicine at Tuskegee University which has graduated approximately 75 percent of the United States' black veterinarians, and the United Negro College Fund (UNCF) which administers 37 private historically black colleges and universities throughout the United States and administers 10,000 scholarships every year. Today, UNCF has raised over $3.6 billion since its inception in 1944.

Dr. Patterson's leadership won him national recognition and earned him an invitation to serve on President Harry S. Truman's President's Commission on Higher Education from 1946-47. This commission called for an important shift in American college education away from European concepts, and towards equality of opportunity. Important developments flowing historically from this Commission's report were the development of the community college network and the Title III of the Higher Education Act of 1965.

Dr. Patterson eventually became a director of the Phelps-Stokes Fund from 1958-1969 where he worked to improve education for youth of all disadvantaged backgrounds. He also founded the nonprofit Robert R. Moton Memorial Institute to improve the recruitment and management processes of HBCUs.

Eventually, Dr. Patterson would receive the Presidential Medal of Freedom from President Ronald Reagan on June 23, 1987 in recognition of his lifetime of leadership and success in the educational field. He received a Candace Award from the National Coalition of 100 Black Women in 1986.

In honor of the profound impact Dr. Patterson had on college education, especially in the African American community, UNCF established the Frederick D. Patterson Research Institute (FDPRI) in 1996. FDPRI is the nation's foremost research institution regarding educational issues facing African Americans from preschool to adulthood. Headquartered in Washington, DC within UNCF headquarters close to Howard University in the Shaw neighborhood of DC, the legacy of Dr. Frederick D. Patterson continues to live on.

Patterson is a member of Alpha Phi Alpha fraternity.

[eretzyisrael]

TEL AVIV — About 2.1 million women worldwide developed breast cancer in 2018, according to the World Health Organization.

Last year also saw some 627,000 fatalities due to breast cancer — nearly all because their cancer had spread to distant organs.

Israeli researcher Neta Erez is trying to find out how the cancer spreads in a bid to stop it.

“Most studies are still done on the primary tumor, but that’s not what kills the patient,” Erez said. “If we can intervene at an early stage, we may be able to prevent metastasis.”

If successful, this could lead to significant improvements in cancer treatment and survivability.

Erez, the chairwoman of the Department of Pathology at Tel Aviv University’s Sackler Faculty of Medicine, is one of many Israeli cancer specialists studying breast cancer, which strikes Ashkenazi Jewish women at three times the rate of the general population. That’s because Ashkenazi women are much more likely to carry mutations in the BRCA1 and BRCA2 genes that lead to extremely high rates of developing cancer.

Even so, 99 percent of breast cancer patients whose tumors are diagnosed and removed at an early stage are still alive after five years. That five-year survival rate drops to 92 percent if the tumor reaches Stage 1 classification, and drops to just 14 percent for patients who have the Stage 4 disease.

The key to improved outcomes, Erez says, is to stop the disease from spreading.

“We no longer look at tumors as a bunch of cancer cells, but as multicellular organs. They actually recruit and hijack lots of so-called normal cells that then become part of the tumor,” she said. “We’re trying to understand the interactions and relationships between those tumor cells and the normal cells that get hijacked.”

October is Breast Cancer Awareness Month. In the United States, where breast cancer is the most common cancer among women, there will be countless fundraising events, marches for cures and other efforts to raise money for research to fight the disease.

The Israel Cancer Research Fund, which raises money in the United States for cancer research at Israeli universities, hospitals and other institutions, has long been a funder of breast cancer research. Erez is one of the organization’s grant recipients.

So is Dr. Gad Rennert, director of the Clalit National Israeli Cancer Control Center in Haifa, who is studying why breast cancer is so prevalent among pre-menopausal women under the age of 45.

“Most cancers develop over a pretty long period, maybe 10 to 15 years,” said Rennert, whose lab is the recipient of a $420,000, three-year ICRF grant split evenly between the City of Hope Cancer Center in Los Angeles and his agency. “So when a woman develops cancer at 35, you’ve got to wonder what happened to her at age 25.”

Rennert’s project is analyzing the DNA of newly diagnosed young women with breast cancer — Stage 1 patients up to 35 years old and Stage 2 patients up to 45 — and testing their DNA for changes in about 130 genes known to be involved in the development of breast cancer.

“I don’t have Phase 2 results yet, but in Phase 1 we identified another 10 percent of women with mutations in other genes or rare mutations in BRCA,” he said. “We’re trying to see if there are other genetic events or unspecified mutations.”

The next phase of Rennert’s study involves evaluating the immune system of women who had been excluded from the previous phase of research based on BRCA1, BRCA2 or other gene mutations.

“Our project is not meant to look for environmental factors, but rather genetics and immunological response,” he said. “We want to see if these women have a weakened immune response to a cancer attack.”

The effort to arrest the spread of breast cancer involves more than cancer experts.

Gilad Bachrach teaches at Hebrew University-Hadassah’s Institute of Dental Science in Jerusalem. A microbiologist who specializes in clinical diseases like tuberculosis and Malta fever, Bachrach has taken a particular interest in Fusobacterium nucleatum — a specific bacterium that was found recently within malignant colon tumors.

Now in the second year of a $50,000-per-year ICRF grant, Bachrach runs one of only five labs worldwide that can genetically manipulate F. nucleatum. Since that particular bacterium in colon cancer originates from the mouth, he speculated that it might reach tumors via blood.

Specifically, a fusobacterial surface protein, Fap2, binds and activates a receptor on immune cells known as TIGIT, thereby suppressing the ability of immune cells to destroy the tumor. Fusobacterium can travel to the colon not only through the gut but also through the blood, meaning it can reach other cancers as well, protecting them from the immune system.

“When you have gum disease, you bleed, and bacteria could enter,” said Bachrach, a former Israeli army tank commander who has done postdoctoral work at the National Institute of Medical Research in London and the National Institutes of Health in Bethesda, Maryland. “We found that they specifically colonized the tumor because they find sugar exposed on cancer cells. Then we looked for other cancers where this sugar is exposed, and one of them is breast cancer.”

To stop the spread of cancer, Bachrach says, clinicians should consider anti-spreading agents, not just typical cancer treatments. It is possible fighting this bacteria will have implications for breast cancer patients.

“Antibiotics are drugs that can kill bacteria,” he said. “At some point, physicians should think about using antibiotics when they’re treating people with cancers.”

Ultimately, Bachrach wants to re-engineer the fusobacterium to turn it into a cancer killer rather than a cancer protector.

“Our long-term goal,” he said, “is to engineer the fusobacteria in order to colonize the cancer and kill it.”

[fusiontechnology-blog1]

ICMR Guidelines

ICMR stands for the Indian Council of Medical Research guidelines. These guidelines are mandatory  and needs  which is to  be followed  for all the biomedical  research among the  country  as per  the  New Drugs  and  Clinical Trials  Rules. ICMR has made a great contribution as a knowledge making agency and contributed in understanding various diseases of national importance such as malaria, tuberculosis, Japanese encephalitis, AIDS (Acquired Immunodeficiency Syndrome), Filariasis, Kala-azar, Leprosy and Poliomyelitis. In addition to this, ICMR has made widespread contributions in the areas of reproduction, nutrition, and maternal & child health, environmental health and occupational and research complimenting health systems. ICMR regional medical research institutes/ centers have been paying in tackling regional health problems further.

Fusion Technology Solutions – Best Clinical Research Course In Pune

These guidelines have explained the three basic ethical principles which include: respect for person, justice, beneficence by instating twelve general principles as follows:

Principle of essentiality:

Research performed should be important for the progression of knowledge that benefits doctors, patients, and all others involved in aspects of health care and also for the environmental and ecological well-being of the planet.

Principles of voluntariness, informed consent and community agreement:

Participants involved in the research must be aware of the research nature and the probable results of the experiments and then must make independent choice without involvement of any influence of the treating doctor, whether to be part of the research or not. When the research treats persons as a research participant, those of voluntariness and informed consent must apply to the community and also to each individual member responsible of the research or experiment.

Principle of non-exploitation:

Participants involved in the research must be compensated for their involvement in the research or experiment. They must be made aware of all the risks involved in the irrespective of their social or educational levels and economic condition attained. Every protocol of research must be involved in the provisions of compensation for the human participants either through appropriate means to cover all predictable and hidden risks.

Principle of privacy and confidentiality:

Acquired significant data for research purpose must be kept confidential to prevent disclosure of any particular identity of the involved participant and must not be disclosed without valid legal and/or scientific reasons.

Principle of precaution and risk minimization:

Care and caution must be taken into consideration at all stages of the research and experiment to avoid research participant from any harm and adverse events. EC has to play an active role in minimization the risk.

Principle of professional competence:

Clinical research trials must be carried out only by competent, capable and qualified persons in their respective fields.

Principle of accountability and transparency:

The experiments conducted by the researchers should be always in honest, fair, impartial and transparent manner after all the full disclosure of his/her interests in research. The research data or the significant information should be retained subject to the principles of privacy and confidentiality for the tenure of minimum 5 years, by the appropriate legal and administrative authority, if needed.

Principle of institutional arrangements:

It is majorly required to consider that all institutional arrangements compulsory to be complete in respect of the research and its following use or applications must be duly made in transparent manner.

Principle of the maximization of the public interest and of distributive justice:

Research study results must be used for the human benefits, particularly the research participants themselves and/or the community not only to those who are socially better off.

 Principle of public domain:

Research study results must be always made in the public through the publications or with other sources. Considerably, before the publications, the detailed significant information of the clinical trials must be made before the start of recruitment via the clinical trials registry which allows the free online access.

Principle of totality of responsibility:  

All the working population in the research directly or indirectly connected should take the professional and moral responsibility.

Principle of Compliance:

All those allied with the respected research work must comply by the guidelines relating to the detailed area of the research. In the process of conducting research ethically, one should follow these above 12 general principles imposed by the ICMR. Moreover, to follow these general principles one should be aware regarding the vulnerable population, informed consent process, post-trial access, therapeutic misconception, and structure and role of ethics committees. Furthermore, these concepts hold the specific significance in the emerging countries, as most of the participants in the research are uneducated and economically backwards, therefore they are discussed precisely in every organization with all the employees and laborers.

[jobsarkariresult-blog]

NIRT Recruitment 2019 Walk in Interview 89 Technician, Consultant, Scientist, Driver, Data Entry Operator Posts Vacancy

NIRT Recruitment 2019 Walk in Interview 89 Technician, Consultant, Scientist, Driver, Data Entry Operator Posts Vacancy

NIRT Recruitment 2019 Walk in Interview (www.nirt.res.in). National Institute for Research in Tuberculosishas release their latest Recruitment notice. This is probably the finest opportunity for meritorious students. First of all NIRT Recruitment total number of vacancy is 89 Technician, Consultant, Scientist, Driver, Data Entry Operator Posts. So, eligible and willing candidate may be waiting…

[govtjob4u-blog]

NIRT Chennai Recruitment 2018 – Walk in for Project Technical Officer & Technician Posts

NIRT Chennai Recruitment 2018 – Walk in for Project Technical Officer & Technician Posts

[ad_1]

Name of the Post: NIRT Project Technical Officer & Technician Walk in 2018

Post Date: 29-06-2018

Total Vacancy: 17

Brief Information: National Institute for Research in Tuberculosis (NIRT), Chennai has published notification for the recruitment of Project Technical Officer & Technician vacancies on temporary basis. Those Candidates who are interested in the vacancy details & completed…

[sudheervanguri]

Recruitment of Project Research Scientist 1 Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi - 221005 Applications are invited in the attached format from Indian nationals for the post of Project Research Scientist 1 (Non-medical) to work on an ICMR sponsored project under the supervision of Dr. Deepak Kumar, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi, India. Title of the project: Targeting cytochrome bd oxidase (cyt-bd) inhibitor for the development of rational drug combination for complete sterilization of Mycobacterium tuberculosis Duration: Three years. The post is purely temporary and co-terminus with the project. Fellowship Amount: Rs. 56,000 + 16% HRA per month Minimum Essential qualifications: First class postgraduate degree, including the integrated PG degree. Second class postgraduate degree, including the integrated PG degree with PhD. For Engineering/IT/CS-First class graduate degree of four years. Desirable qualifications: Candidates with knowledge and skills in synthesis, column chromatography, and spectroscopic characterization are desired. The candidates should have a basic degree in pharmacy (B. Pharm). The graduate degree in M. Pharm/M. S. (Pharm.)/M. Tech (Pharm)/M. Tech in Medicinal Chemistry/Pharmaceutical Chemistry, and Pharmacognosy with GATE/GPAT/CSIR-NET or equivalent examination. Age limit: 35 Years Vacancy Details: Position Title Project Research Scientist 1 Job Type Temporary, Co-terminus with the project Duration Three years Fellowship Amount Rs. 56,000 + 16% HRA per month Minimum Qualifications First class postgraduate degree, Second class postgraduate degree with PhD, or First class graduate degree of four years for Engineering/IT/CS Desirable Qualifications Basic degree in pharmacy (B. Pharm), Graduate degree in M. Pharm/M. S. (Pharm.)/M. Tech (Pharm)/M. Tech in Medicinal Chemistry/Pharmaceutical Chemistry, and Pharmacognosy with GATE/GPAT/CSIR-NET or equivalent examination Age Limit 35 Years Interested candidates are requested to send their applications in the attached format, giving detailed information on educational qualification, research experience, and publications if any via email to Principal Investigator, Dr. Deepak Kumar at deepak.phe@itbhu.ac.in on or before 29th December 2023. Please write “Application for Project Research Scientist 1” in the subject line of the email. The shortlisted candidates will be intimated by email. No TA/DA will be paid if called for an interview. [caption id="attachment_58114" align="aligncenter" width="1200"] iit-bhu-recruitment-project-research-scientist[/caption] General Instructions: The PI has the discretion to restrict the number of candidates to be called for an interview to a reasonable limit based on qualifications and experience. Only shortlisted candidates will be communicated to appear in the interview, and no other communications in this regard will be entertained. Original certificates and self-attested copies of all certificates need to be presented before the interview for verification. Venue of Interview: Department of Pharmaceutical Engineering & Technology, IIT (BHU), Varanasi- 221005, E-mail: deepak.phe@itbhu.ac.in. Application should be strictly according to the attached format. Also, refer to the website: www.iitbhu.ac.in/positions_available. Dr. Deepak Kumar Principal Investigator Department of Pharmaceutical Engineering & Technology, IIT(BHU), Varanasi-221005 Email: deepak.phe@iitbhu.ac.in IIT BHU Recruitment Join as Project Research Scientist. PDF

[naukribatao-blog]

NIRT Recruitment 2017 – 04 Multiple Posts – Last Date 03 March 2017

NIRT Recruitment 2017 – 04 Multiple Posts – Last Date 03 March 2017

Sarkari Naukri 2017 in National Institute For Research In Tuberculosis Job Details Designation Name Project Technician III (Field Worker) Project Technical Assistant (Social Work) Total Vacancies : 04 Posts Vacancies Details : Designation Vacancy Project Technician III (Field Worker) 02 Posts Project Technical Assistant (Social Work) 01 Post Age Limit : Designation Age Project Technician III…

[lansarstores]

Lansar Jobs

NIRT Recruitment 2021 – 09 Project Driver Post | Apply Online National Institute for Research in Tuberculosis will release the 09 Project Driver and Mechanic Jobs this Year 2021. Those Candidates who are interested in the vacancy details & completed all eligibility criteria can read the Notification & Apply Online. To apply for the National Institute for Research in Tuberculosis Recruitment…

[gktodaycurrentaffairs]

NIRT Recruitment 2021 Apply 02 Scientist Medical Vacancies

NIRT Recruitment 2021 Apply 02 Scientist Medical Vacancies

ICMR NIRT Recruitment 2021: ICMR – National Institute for Research in Tuberculosis (NIRT) Chennai invites applications from eligible candidates for recruitment of Scientist B (Medical) on temporary basis under different projects.The Walk in Test / Interview scheduled to be held on 18th March 2021. Name of the Post No of Vacancies Scientist B (Medical) 02 ✅ Job Location: Chennai, Vellore. ✅…

[stephenasj]

NIRT Recruitment 2021 | Apply 35 LAB Assistant and Health Assistant Post

NIRT Recruitment 2021 | Apply 35 LAB Assistant and Health Assistant Post

  NIRT Recruitment 2021 | 35 Vacancies | LAB Assistant & Health Assistant | 10th Pass to Any Degree | Interview Date – 10/03/21 and 11/03/21 | Tamil Nadu Government Jobs 2021 | Direct Interview Tamilnadu NIRT Recruitment 2021 National Institute for Research in Tuberculosis Officially Released this Notification. NIRT Officials are inviting applications from the eligible and interested candidate.…

[orbemnews]

Emil Freireich, Groundbreaking Cancer Researcher, Dies at 93 Dr. Emil Freireich, a relentless cancer doctor and researcher who helped devise treatments for childhood leukemia that dramatically transformed the lives of patients thought to have little hope of survival, died on Feb. 1 at the University of Texas MD Anderson Cancer Center in Houston, where he had worked since 1965. He was 93. His death was confirmed by his daughter Debra Ann Freireich-Bier. The hospital said he had tested positive for Covid-19 but it has not yet been determined as the cause of death. Dr. Freireich was a transformational, magnetic and occasionally abrasive figure who spent his career at the National Cancer Institute and MD Anderson exploring for six decades new treatments for cancer and training hundreds of doctors to follow in his path. “He oversaw research across all cancers, guiding and dictating the evolution of protocols, implementing them and publishing results that were adopted around the world,” said Dr. Hagop Kantarjian, chair of the leukemia department at MD Anderson. When Dr. Freireich (pronounced FRY-rike) started work at the N.C.I., in Bethesda, Md., in 1955, acute childhood leukemia was considered a death sentence. Entering the ward where the children were being treated, he recalled their hemorrhaging because their blood had virtually no platelets, the disc-shaped cells that clot blood. It was like an abattoir, his boss, Dr. C. Gordon Zubrod, told him. “They bleed from out of their ears, from their skin,” Dr. Freireich told the author Malcolm Gladwell in “David and Goliath: Underdogs, Misfits and the Art of Battling Giants” (2013). “There was blood on everything. The nurses would come to work in the morning in their white uniforms and go home covered in blood.” Dr. Freireich, a hematologist and oncologist, tested his hypothesis that the lack of platelets was causing the hemorrhaging by mixing some of his own blood with some of the children’s. “Would it behave normally?” he said in interview for an N.C.I. oral history project in 1997. “Sure enough, it did.” Further testing, done to persuade his skeptics at the cancer institute, proved him right. But he had another problem: the blood that the children had been receiving lacked the platelets needed for their blood to clot because it was at least 48 hours old. The platelets had deteriorated and were useless. Dr. Freireich argued successfully for the use of freshly donated blood that could be transfused as quickly as possible and did not languish in the institute’s blood bank. A minister who was the father of one of the patients once brought in 20 of his congregants to donate blood. Looking for a more effective way to deliver platelets to his patients, Dr. Freireich began to design a machine to extract platelets from white and red blood cells. He soon found an unexpected ally in George Judson, an IBM engineer whose son had leukemia and had shown up at the institute to offer his expertise. Soon they were collaborating on a continuous-flow blood separator that proved far more efficient at delivering platelets than blood transfusions. (The separator, which used a high speed centrifuge, was patented in 1966.) But Dr. Freireich’s most important, enduring achievement was in using a combination of drugs to send leukemia into remission. He explored options in chemotherapy with several N.C.I. colleagues, including Dr. Emil Frei III, who was known as Tom. They made an aggressive assault on childhood leukemia by devising a cocktail of four drugs that would be administered simultaneously — a technique similar to the three-drug regimen used to treat tuberculosis — so that each one would attack a different aspect of the physiology of the cancer cells. “It was crazy,” Dr. Freireich told Mr. Gladwell. “But smart and correct. I thought about it and I knew it would work. It was like the platelets. It had to work!” But not without peril and concern. Some of the children nearly died from the drugs. Critics called Dr. Freireich inhumane for experimenting with his young patients. “Instead, 90 percent went into remission immediately,” he told USA Today in 2015. “It was magical.” But temporary. One round of the cocktail was not enough to eliminate all the cancer so Dr. Freireich and his team treated them with the drugs monthly for more than a year. When he and Dr. Frei received the prestigious Albert Lasker Clinical Medical Research Award in 1972, the percentage of children who lived at least five years after their leukemia diagnosis was 30 percent. Today — using similar regimens that Dr. Freireich and Dr. Frei pioneered — the survival rate is 90 percent, according to the American Cancer Society. Dr. Frei died in 2013. Emil J Freireich was born on March 16, 1927, in Chicago. His mother, Mary (Klein) Freireich worked long hours at a sweatshop after her husband, David, died when Emil was 2. He was put in the care of an Irish maid who became his surrogate mother. Soon after he turned 9, his mother remarried and quit her job; she and her new husband dismissed the maid. “I never forgave my mother for that,” Dr. Freireich told Mr. Gladwell. He excelled in physics in high school, where he won first prize in a science contest. His physics teacher encouraged him to go to college where his goal was to be a family doctor like the one who treated his family. “He worked for nothing and always wore a suit and tie and always looked so dignified,” Dr. Freireich told the online publication of the American Society of Clinical Oncology in 2015. After receiving a bachelor’s degree in medicine in 1947 from the University of Illinois, Chicago, he got his medical degree in 1949 from the university’s College of Medicine, also in Chicago. His internship at Cook County Hospital, also in Chicago, ended after he confronted a nurse for putting a patient with heart failure in the so-called “dying room” rather than keeping him in the ward where Dr. Freireich had treated him. He was labeled a “troublemaker,” he said. He then served his residency at nearby Presbyterian Hospital (now part of Rush University Medical Center), then moved to Boston for a fellowship at a hospital where he studied anemia. While there, he met a nurse, Haroldine Lee Cunningham, whom he married in 1953. In 1953, he was drafted into the Army but was able to join United States Public Health Service and work at the N.C.I., an arm of the National Institutes of Health. At their first meeting, Dr. Zubrod, his boss, asked him, “Freireich, what do you do?” “I’m a hematologist,” Dr. Freireich recalled responding and watched as Dr. Zubrod scratched his head telling him, “Freireich, you should cure acute leukemia in children.” And I said, “Yes, sir.” After a decade of devising treatments for childhood leukemia at the N.C.I., Dr. Freireich (and Dr. Frei) were recruited to MD Anderson in 1965. Together they formed the Department of Developmental Therapeutics and hired scientists to develop drug combinations for various cancers, including adult leukemia, lymphoma and Hodgkin’s disease, using the same methodologies they used to treat childhood leukemia. Because of Freireich’s larger-than-life personality and magnetism, he attracted people from all over the world to study with him,” Dr. Kantarjian said. Dr. Freireich retired in 2015 but continued to teach and consult at MD Anderson. Besides his wife and Ms. Freireich-Bier, Dr. Freireich is survived by another daughter, Lindsay Freireich; two sons, David and Tom; six grandchildren and three great-grandchildren. Dr. Freireich analogized the early fight to cure childhood leukemia to being in a battle in which he and the N.C.I. team had an alliance that was “forged under fire.” To cure cancer, he added: “Motivate people and give them the opportunity People are innately motivated. Nobody likes to be lazy and do nothing. Everybody wants to be significant.” Source link Orbem News #cancer #Dies #Emil #Freireich #Groundbreaking #researcher